This shows the main results of the EMBARK trial, comparing Metatasis Free Survival and PSA Recurrence Free Survival for three groups: Enzalutamide only, Lupron only, or combined Enzalutamide + Lupron.
The best survivals were for the combination of Enzalutamide + Lupron.
Enzalutamide is a 2nd generation Anti-Androgen, and Lupron is an anti-testosterone agent.